Combination Therapy of Pegylated Interferon alpha 2b (PegIFN) and Adefovir Dipivoxil (ADV) in Chronic Hepatitis B (CH-B) Patients Reduces the Reservoir of Transcriptionally Active…
F Metzler, K Wursthorn, B Zoellner, P Buggisch, M Zankel, C Fischer, J Petersen · Zeitschrift für Gastroenterologie · 2005 · Heft 01
Bibliografische Angaben
Zusammenfassung
Introduction: We previously demonstrated that 48 weeks of ADV therapy resulted in a significant median 73% reduction of serum HBsAg (Werle, Gastroenterology 2004). Changes in HBsAg were significantly and positively correlated with changes in intrahepatic cccDNA, total intrahepatocellular HBV DNA and serum HBV DNA. The number of HBcAg positive hepatocytes remained stable. Aim: To determine the reduction of serum HBsAg titer from baseline to end-of- treatment in CH-B patients undergoing antiviral combination therapy. Methods: 21/26 patients with HBeAg positive and negative CH-B completed a 48-week course of treatm…
